The story of how India’s largest generics drug maker dealt with the discovery of deep gaps in its drug trial data
The initial disclosure of fraud at Vimta Labs Ltd (in 2004), the company Ranbaxy Laboratories Ltd had hired to test its AIDS drugs, was like a teetering domino, threatening to topple interconnected drug applications approved by regulators around the world. As charitable organizations asked the company for underlying data to support its claims, the problem confronting Ranbaxy executives had become almost unsolvable. Drugs that had never been tested, or whose tests revealed a failing product, were now due to be re-registered in countries around the world. Much of the raw data didn’t match what the company had filed with regulators.